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the progesterone receptor (PR), had been purified to
homogeneity (Schrader et al., 1977). Studies using puri-
fied receptor fractions, particularly those of PR and the
glucocorticoid receptor (GR; Wrange et al., 1984),
helped to sketch a model of receptor activation in which
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steroid binding induced dimerization and increased af-
finity of the receptor for specific cis-acting DNA se-The nuclear receptor (NR) superfamily of transcription
factors regulates gene expression in response to en- quences (hormone response elements, or HREs; Payvar
et al., 1982) to effect an increase in RNA production—adocrine signaling, and recruitment of coregulators af-
fords these receptors considerable functional flexibil- model which has survived essentially intact to this day.
By the end of the decade, cDNAs had been cloned thatity. We will place historical aspects of NR research in
context with current opinions on their mechanism of encoded first GR (Hollenberg et al., 1985) followed by the
estrogen receptor (ER), PR and receptors for androgenssignal transduction, and we will speculate upon future
trends in the field. (AR), thyroid hormone (TR), all-trans and 9-cis retinoic
acid (RAR and RXR), and vitamin D (VDR) (reviewed in
detail in Evans, 1988). At this point, the field was primed
to bring a substantial body of experimental evidence toPreface
The coordinated expression of gene networks in numer- bear upon the structural and functional dissection of NRs.
ous physiological, developmental, and metabolic pro-
cesses can be ascribed in large part to a superfamily NRs: A Superfamily Portrait
of ligand-inducible transcription factors, the nuclear re- While a structural relationship among receptors for ste-
ceptors (NRs). Abundant evidence has identified NRs roid ligands had been presumed, it was only after com-
as mediators of the transcriptional response to a variety parison of the deduced encoded amino acid sequences
of ligands: acting as signaling conduits in steroid regula- of the cloned receptor cDNAs that the concept of an
tion of reproductive processes and thyroid/retinoid reg- evolutionarily related superfamily of transcription fac-
ulation of development; as metabolic barometers in the tors—the NR superfamily—was validated. NRs have been
regulation of bile acid and cholesterol biosynthesis; and historically divided into type I receptors (essentially the
as prominent etiological factors in diseases ranging from classical steroid receptors), which undergo nuclear trans-
breast and prostate cancer to diabetes and obesity. In location upon ligand activation and bind as homodimers
addition to offering a brief historical summary of the to inverted repeat DNA half sites, and type II receptors
functional characterization of NRs, this review will em- (TR and RAR, among others), which are often retained
phasize the evaluation of concepts and models that in the nucleus regardless of the presence of ligand and
more recent research efforts have generated to place usually bind as heterodimers with RXR to direct repeats.
in context future goals toward which the field is currently The recognition of the NR superfamily prompted a series
striving. of experiments in which degenerate oligonucleotide se-
quences, based upon conserved regions of NR cDNAs,
In the Beginning were used in low-stringency screening experiments to
In most instances, the observation that a hormone identify clones that were then subjected to sequence
bound specifically to tissue preparations preceded by analysis. Beginning with the estrogen receptor-related
several decades the purification of a NR and the cloning receptors (ERRs; see Evans, 1988), these experiments es-
of a NR cDNA. The initial characterization of steroid tablished the existence of previously unidentified cDNAs
hormone action focused upon the striking proliferative encoding proteins that contained domains resembling
properties of these hormones in their target tissues. The those present in characterized NRs. Since ligands for
concept of high-affinity, tissue-specific, steroidophilic these proteins had not been previously identified and
factors—receptors—as mediators of hormone function the prediction of ligand structure from their primary LBD
gained credence from pioneering tissue binding studies sequences was (and remains) a practically impossible
(reviewed in Jensen and Jacobson, 1962). Subsequent task, they were designated “orphan NRs” (ONRs) and
attempts to define a chronology for the effects of these are categorized in the type III class within the NR super-
molecules in the oviduct, uterus, and other target tissues family (Giguere, 1999; Mangelsdorf and Evans, 1995).
established cell- and ligand-specific increases in mRNA While scope limitations preclude a detailed discussion
and protein synthesis as primary events in their action of ONRs in this review, the regulatory influences that
(O’Malley and McGuire, 1968) and substantiated a basic impinge upon type I and II NRs also apply generally to
linear model of steroid hormone action from ligand to the ONRs.
target gene product (Means et al., 1972). Biochemical In the next several years, following the cloning of ex-
purification strategies used radiolabeled ligands to con- pressible NR cDNAs, the transient transfection-based
siderable effect to overcome the sparse cellular levels HRE-reporter assay became the workhorse for labora-
of many NRs, and by the late 1970s a steroid receptor, tories pursuing a molecular rationale for NR action (Ev-
ans, 1988). The advent of molecular biology afforded
investigators the opportunity to mix and match the au-1Correspondence: berto@bcm.tmc.edu
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Figure 1. Shared Functional Domains of NR Superfamily and SRC/p160 Family Members
(Top) General structure of NRs. AF-1 is embedded in the N terminus of type I NRs and AF-2 in the C terminus of all NRs. Intramolecular
communication between the two functions is thought to be involved in coregulator function. The A/B domain is prominent in type I NRs and
is considerably foreshortened in type II receptors.
(Bottom) General structure of the SRC/p160 family. The CBP interaction domain and the CARM1 interaction domain overlap with the transferable
activation domains 1 and 2 of the SRC/p160 family, respectively.
tonomous functional modules of the receptors, to gener- acterization there was abundant empirical evidence that
pointed to their existence. This stands in contrast to theate specific domain and point mutations, and to probe
the specificity of the cis-acting HREs, all in the context rapid characterization over the last several years of NR
coregulators. As early as three decades ago, aspectsof a single functional assay of receptor action. The iden-
tification of signature-shared regions—a conserved zinc of NR action were being ascribed to the interaction of
receptors with hypothetical non-DNA “nuclear acceptor”finger-based DNA binding domain (DBD) and a C-ter-
minal ligand binding domain (LBD), containing regions molecules (Spelsberg et al., 1971; Yamamoto, 1985).
While not calling coregulators by name, this thesis gen-mediating ligand binding and dimerization—added mo-
lecular detail to the biochemical description of receptors erated speculation for a role for intermediary factors in
NR action. Tangible evidence for the recruitment by acti-as hormone-inducible DNA binding factors (Figure 1A;
reviewed in Evans, 1988; Tsai and O’Malley, 1994). More- vated receptors of factors other than their presumptive
bedfellows—RNA polymerase and the basal transcrip-over, the development of a cell-free system that recapit-
ulated receptor activity in vivo facilitated the functional tion machinery—came initially from yeast experiments
based on transcriptional interference (squelching; Gillanalysis of receptor domains (Bagchi et al., 1992). In
addition to the regions mentioned above, constitutive and Ptashne, 1988) and subsequently from squelching
noted between cotransfected receptors in reporter(AF-1) and ligand-dependent (AF-2) activation functions
were identified, along with repression domains (re- assays in mammalian cells (Meyer et al., 1989). The tis-
viewed in Tsai and O’Malley, 1994). The schizoid func- sue-selective transactivation properties of autonomous
tionality of NRs, alternating between activation and re- receptor activation (Nagpal et al., 1992) and later repres-
pression in response to specific molecular cues, is now sion (Baniahmad et al., 1995) functions further reinforced
known to be attributable in large part to their recruitment the notion of intermediary factors in NR function. Build-
of a diverse group of ancillary factors, the coregulators. ing upon these initial molecular approaches, biochemi-
Although the remainder of this review will focus largely cal strategies provided the first evidence that ligand
on coregulators, the more recent cloning of NRs such as binding resulted in the recruitment by ER of associated
ER (Kuiper et al., 1996), which has a pharmacological molecules in mammalian cells (Cavaille`s et al., 1994;
activation profile distinct from that of ER (Katzenellen- Halachmi et al., 1994). Within the same decade, cDNAs
bogen et al., 2000), suggests that the pursuit of novel encoding close to thirty of these molecules were cloned
NR functions remains an important area in this field. (see below), representing a rapid accumulation of infor-
mation that is yet to be organized into a coherent model
of their biological significance. Table 1 summarizes re-Enter Coregulators
The discovery of NRs had its roots in decades of histori- cently described properties of selected coregulators.
They are (broadly) divisible into coactivators, whichcal endocrinology and pathology, and prior to their char-
Review
467
Table 1. Selected Nuclear Receptor Coregulators
Coregulator Selected Recent Reports
Coactivators
RIP140 Initially defined as a coactivator (Cavaille`s et al., 1995); may also function as a corepressor (Windahl et al.,
1999).
SRC-1/NCoA-1 Targeted by MAP kinases (Rowan et al., 2000).
TIF2/GRIP-1/SRC-2 Initially identified as a coactivator, also mediates promoter-dependent corepression (Rogatsky et al., 2001).
p/CIP/RAC3/ACTR/AIB-1/ Present in IK complex; phosphorylated by IK; null deletion preferentially impacts growth factor
TRAM-1/SRC-3 mediated-physiology (Xu et al., 1998, 2000; Wang et al., 2000).
CBP/p300 Methylation by CARM-1 uncouples interaction with CREB (Xu et al., 2001), acetylates ACTR/SRC-3 to uncouple
its interaction with NR (Chen et al., 1999b).
TRAPs/DRIPs Disruption of TRAP220 subunit results in embryonic lethality (Ito et al., 2000).
PGC-1 Transduces GR- and CREB-mediated hepatic gluconeogenesis (Herzig et al., 2001; Yoon et al., 2001);
coordinates transcription and RNA processing (Monsalve et al., 2000); sequestration by a corepressor
reversed by MAPK-mediated phosphoyrlation (Knutti et al., 2001).
CARM-1 Recruited by SRC-1 to potentiate transcriptional coactivation (Chen et al., 1999a); related to another protein
methyltransferase, PRMT-1 (Wang et al., 2001); see also CBP/p300.
PRIP/ASC-2/AIB3/ Contains NR box; possible bridging factor between CBP/p300 and DRIP-130, a component of the
RAP250/NRC DRIP complex; gene identical to one overexpressed in breast cancer (Caira et al., 2000; Lee et al., 1999;
Mahajan and Samuels, 2000; Zhu et al., 2000).
GT-198 Broad-spectrum coactivator whose gene localizes to breast cancer susceptibility locus; phosphorylated
by a variety of kinases in vitro (Ko et al., 2002).
SHARP, CoAA, p68, p72 Coactivators containing RNA-binding domains (Endoh et al., 1999; Iwasaki et al., 2001; Shi et al., 2001).
Corepressors
SMRT Subcellular distribution induced by MAP kinase-mediated phosphorylation (Hong and Privalsky, 2000);
distributed among a variety of repressor complexes (reviewed in Rosenfeld and Glass, 2001).
NCoR Found in a variety of repressor complexes (reviewed in Rosenfeld and Glass, 2001); functions with a specific
HDAC to mediate transcriptional activation at a subtype of retinoic acid HRE (Jepsen et al., 2000).
REA Selective ER corepressor; competes with SRC-1 for binding to liganded ER (Montano et al., 1999).
Although many other coregulators exist, constraints upon space and reference number limit this table to a brief update on selected recent
reports. For a more in-depth discussion of earlier studies, the reader is encouraged to refer to previous reviews (McKenna et al., 1999;
Rosenfeld and Glass, 2001).
mediate the potentiating functions of activated recep- partial resistance to steroid hormones (Xu et al., 1998,
2000; Wang et al., 2000) confirmed their coactivatortors, and corepressors, which transduce the attenuating
functions of nonactivated receptors. More recent evi- function in a physiological context. As with NRs, the
modular construction of coactivators facilitated the lo-dence indicates that coregulators serve as stages upon
which subplots of functional complexity, in the form of calization of autonomous activation domains believed
to mediate interactions with the basal transcription ap-combinatorial interactions and specific posttransla-
tional modifications, are acted out during the intricate paratus—see review in McKenna et al. (1999) and Ro-
senfeld and Glass (2001).programs of transcriptional regulation in which NRs par-
ticipate. The SRC/p160 family (Figure 1B) is structurally and
functionally distinguishable from other molecules that
fulfilled some or all of the experimental properties thatCoactivators
initially defined NR coactivators—the acetyltransferasesThe functional autonomy of the receptor LBD permitted
CBP (Kamei et al., 1996) and p300 (Chakravarti et al.,its adaptation to the yeast two-hybrid protein-protein
1996); members of the TRAP/DRIP complex (Fondell etinteraction assay, and a pioneering screen identified an
al., 1996; Rachez et al., 1998); the ubiquitin ligase E6-array of TR-interacting factors in a HeLa cDNA library
AP (Nawaz et al., 1999); the ATP-coupled chromatin(Lee et al., 1995). The cloning in rapid succession of
remodeling SWI/SNF complex (Fryer and Archer, 1998;mammalian cDNAs encoding SRC-1/NCoA-1 (Onate et
Yoshinaga et al., 1992); the RNA coactivator, SRA (Lanzal., 1995; Kamei et al., 1996), GRIP-1/TIF2/SRC-2 (Hong
et al., 1999); the protein methylases CARM-1 andet al., 1996; Voegel et al., 1996), and p/CIP/RAC3/ACTR/
PRMT-1 (Chen et al., 1999a; Wang et al., 2001); andAIB-1/TRAM-1/SRC-3 (Torchia et al., 1997; Anzick et al.,
members of the basal transcription machinery, in partic-1997; Chen et al., 1997; Li et al., 1997; Takeshita et al.,
ular TBP and the TAFs (Naar et al., 2001). A recurring1996) identified a family of ligand-recruited NR coactiva-
structural feature of the protein coactivators is antors, the SRC/p160 family. The designation of the three
-helical LXXLL motif, or NR box (Heery et al., 1997),members of this family (and other proteins) as NR coacti-
present from a single to several copies in many coactiva-vators was initially predicated upon their nuclear local-
tors, which is implicated in their ligand-dependent re-ization, their ability to interact with and amplify ligand-
cruitment by the LBD-embedded activation functiondependent functions of NRs on HRE-linked reporter
(AF-2) of NRs. Moreover, several functional propertiesgenes, and their capacity to relieve NR squelching
are common across different groups of coactivators.(Onate et al., 1995). The subsequent observation (in mice
in which the coactivator gene had been deleted) of a Acetyltransferase activity, for instance, with which co-
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Figure 2. Model of Combinatorial NR-Mediated Transcriptional Initiation
Initial binding of ligand results in dissociation of corepressors and recruitment of SWI/SNF chromatin remodeling machines to modify chromatin
domains. Binding of SRCs and CBP results in local acetyltransferase activity and disruption of local nucleosomal structure. Kinase-mediated
signaling pathways may communicate directly with NR-regulated promoters. AF-1 phosphorylation might serve to further consolidate ligand-
dependent NR-SRC interactions or to recruit SRCs directly to the promoter in the absence of ligand. TRAP/DRIP directly contacts components
of the basal transcription machinery to effect transcriptional initiation, and certain TAFs may afford some additional input into promoter-
specific NR transcription. The extent of overlap in binding of complexes to the promoter is currently unclear. Local coactivator requirements
may vary—for example, a promoter in a readily accessible chromatin context may not require significant chromatin remodeling or histone
acetyltransferase activity for assembly of a preinitiation complex.
activators are thought to target histones and other pro- els: (1) the molecular events that direct cyclical interac-
tions at individual promoters, and (2) the global factorsteins to fashion a transcriptionally permissive environ-
ment at the promoter (Figure 2), is possessed by CBP that contribute to combinatorial gene expression on the
wider promoter-, ligand-, and cell type-specific levels.(Bannister and Kouzarides, 1996), PCAF (Yang et al.,
1996), and members of the SRC family (Chen et al., 1997; The initial characterization of coregulators, colored to
some extent by the reporter assays in which their prop-Spencer et al., 1997).
erties were first manifest, emphasized their propensity
to amplify or silence transcription when overexpressedCorepressors
with receptor. Given the well-documented tissue selec-Repression by NRs in many ways closely mirrors the
tivity of NR action, the realization that these coactivatorsmanner in which they effect transcriptional activation.
have, apart from a few exceptions (such as FHL-2; MullerAnalogous to coactivators, NR corepressor (N-CoR;
et al., 2000), a relatively broad tissue distribution pattern,Horlein et al., 1995) and silencing mediator of retinoid
was food for thought. The first hints of a mechanisticand thyroid receptors (SMRT; Chen and Evans, 1995)
rationale for the puzzling plurality of NR coregulatorsare recruited by NRs in the absence of ligand or in the
were provided by studies describing promoter-specificpresence of NR antagonists such as Tamoxifen and
coregulator requirements (Korzus et al., 1998; Puigs-RU486. Moreover, recognition by transcriptionally inert
erver et al., 1998). More recently, promoter identity hasNRs of corepressors is mediated by amphipathic helical
been shown to effect functional inversion among coreg-peptides called “CoRNR boxes” (Hu and Lazar, 1999),
ulators, such that corepressors can become coactiva-which are similar to the previously characterized coacti-
tors (Jepsen et al., 2000) and vice versa (Rogatsky etvator NR boxes. In addition to their structural similarities,
al., 2001; Xu et al., 2001). In addition, variations in ligand-corepressors are functionally comparable to coactiva-
specified recruitment of coactivators (Katzenellenbogentors. Histone deacetylation, for example, appears to an-
et al., 2000) and/or dissociation of corepressors may betagonize coactivator acetyltransferase activity, although
a supplementary source of signaling flexibility at NR-corepressors, lacking intrinsic deacetylation domains,
regulated promoters. To further muddy the waters, core-require recruited factors such as Sin3 and histone
pressors may be capable of binding to liganded receptordeacetylases (HDACs) to achieve this (Heinzel et al.,
to sensitize the transcriptional response to ligand (Mon-1997; Nagy et al., 1997).
tano et al., 1999), a fact conceivably attributable, at least
in part, to the structural symmetry between the NR boxNRs, Coregulators, and Genes: A Complex
and the CoRNR box.Relationship
The interface between receptor AF-2 elements andThe goal of understanding the stringent spatiotemporal
the coregulator NR box has been the subject of intensecoordination of gene expression that NRs effect in re-
study as a potentially rewarding target for peptide-sponse to diverse developmental, physiological, and
metabolic cues can be approached on at least two lev- based manipulation of NR pharmacology (Norris et al.,
Review
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1999). Our laboratory (Smith et al., 1997) and others mediated cellular signaling pathways, and while the abil-
ity of protein kinases to modulate NR function is familiar(Graham et al., 2000) have speculated that coregulators
ground, there is growing evidence that NR coregulatorsmay play an important role in interpreting the tissue
themselves are prime targets for control by these path-specificity of many NR ligands and selective receptor
ways. This modulation can take the form of enhance-modulators (SRMs) such as Tamoxifen and Raloxifene.
ment of coregulator enzymatic activities such as acety-This model remains clinically relevant as SRMs continue
lation (Ait-Si-Ali et al., 1998); promoting the recruitmentto be identified and characterized and as the role of NRs
of other coregulators (Font de Mora and Brown, 2000);and coregulators in metabolic and neoplastic diseases
or the dismantling of inhibitory coregulator complexesemerges. Detailed crystallographic dissections of NR
(Knutti et al., 2001). In addition, liganded NRs recruitLBDs and the AF-2/NR box complex (Feng et al., 1998;
cytoplasmic members of kinase signaling cascadesNolte et al., 1998; Shiau et al., 1998) have identified a
such as the MAP kinase (Boonyaratanakornkit et al.,ligand-induced hydrophobic cleft and an adjacent ionic
2001) and PI3K pathways (Simoncini et al., 2000)—clamp as principal determinants of the interaction of
examples of the historical “nongenomic” component ofAF-2 with the NR box. A model is emerging in which
receptor action—effectively challenging the definition ofligand-specified variations in the AF-2 relief map, along
coregulators as nuclear entities with functions restrictedwith covalent modifications effected by other signaling
to NR-regulated promoters. The identification of coregu-molecules, can generate a tremendous diversity in the
lators as components of these diverse signaling path-capacity of a receptor to recruit coregulators on a pro-
ways reinforces the notion that they may serve as gen-moter- and cell-type specific basis.
eral control panels for integrating multiple afferentGiven, then, the multiplicity of regulatory strata that
stimuli into an appropriate cellular response. Whileexist to tweak receptor action, it can be appreciated
speculation exists as to the mechanistic consequencesthat without the abundance of coregulators identified
of kinase-mediated modification, it may influence theto date, the remarkable context dependency of NR tran-
combinatorial recruitment of coactivator into active tran-scriptional regulation would be significantly compro-
scriptional complexes at distinct promoters (Figure 3).mised. It has become clear from work in our laboratory
Recent studies support the notion that kinase-medi-and others that coregulators are organized in vivo into
ated modification might be a mechanism for directlycomplexes (Figure 2) that are primed for recruitment by
altering the tissue- and promoter-specific functionalityNRs in response to appropriate cues (Fondell et al.,
of coregulators. For example, the coactivator PGC-11996; McKenna et al., 1998; Rachez et al., 1998). Intrigu-
was initially characterized as a dedicated UPC-1 coacti-ingly, many of these complexes share subunits (re-
vator in brown fat cells (Puigserver et al., 1998), raisingviewed in Rosenfeld and Glass, 2001), suggesting that
the intriguing possibility of the existence of promoter-perhaps we are viewing in these biochemical complexes
specific coactivators. More recent data suggests, how-a molecular bucket brigade in which subunits are traded
ever, that in liver cells, targeting of PGC-1 by the cAMPand switched out, a mechanism that may contribute to
signaling axis facilitates its potentiation of CREB- andcyclical assembly of coregulator complexes (Freeman
GR-mediated induction of genes encoding key gluco-and Yamamoto, 2001; Shang et al., 2000). Recent work
neogenic enzymes, such as glucose-6-phosphatase, re-has elucidated the mechanisms that regulate the fine-
sulting in increased glucose output (Herzig et al., 2001;tuning composition of these complexes, such that a
Yoon et al., 2001). Conceivably, in these cases a tissue/selective transcriptional response to any one of a variety
signaling pathway-specific pattern of PGC-1 phosphor-of afferent signals, or an aggregate response to multiple
ylation is directing its communication with complexesstimuli, can be effected.
controlling the transcriptional output of the gluconeo-
genic promoters, although the precise mechanism is
Regulating the Coregulators unclear. These data are a signal reminder of the complex
Coactivators appear to be subject to modulation by se- interplay between parallel signaling conduits and the
lective repressor molecules, such as RIP140 (Cavaille`s role that coregulators play in mediating this crosstalk.
et al., 1995; Windahl et al., 1999), that bind to them and Among coregulators, SRC family members and CBP
antagonize their function. Perhaps more importantly, a appear to be particularly prone to modification by ki-
variety of targeted posttranslational modifications exert nase-mediated pathways, presumably permitting these
considerable control over the functional relationships signaling pathways to directly influence events at a
between NRs, their coregulator complexes, and their broad range of NR-regulated promoters (Figure 2). Intu-
cognate gene networks. No type of covalent modifica- itively, the modular construction of coactivator and core-
tion, it seems, is unworthy of a role in modulating coregu- pressor complexes can create an array of templates
lator function. Some of these, such as acetylation (Chen that constantly evolves and morphs in response to a
et al., 1999b) and ubiquitination (Lonard et al., 2000), variety of stimuli. It is this plasticity that likely contributes
appear to alter the half-life of molecules in the complex; to the capacity of NRs and coregulators to integrate
some, such as phosphorylation, can specify the com- and execute complex programs of gene expression. An
partmentalization or activity of a coregulator within the intriguing scenario is that coactivators and corepressors
cell (Hong and Privalsky, 2000); and others, such as are programmable, and through specific sequences of
methylation, may potentiate coregulator function by tar- posttranslational modifications, they can serve as mem-
geting histones to complement the acetyltransferase ory cards to sensitize specific promoters and/or cell
activity of other coregulators (Chen et al., 1999a; Wang types for subsequent transcriptional responses. Indeed,
et al., 2001). in support of this assertion, certain coactivators are
known to have a low rate of turnover within the cell. TheMany modifications originate in a variety of kinase-
Cell
470
Figure 3. Does the Squeaky Wheel Get the Grease?
Apportioning of coregulator function among distinct kinase signaling pathways may occur on a supply and demand basis, according to unique
phosphorylation codes that determine the functional specificity of the coregulator for distinct NRs and promoters. Abbreviations: GF, growth
factors; PKA, protein kinase A; and MAPK, MAP kinases.
results of experiments that will probe tissue-specific such as adenovirus and papillomavirus appear to cap-
ture coregulators frequently when they infect cells (Lund-variations not only in coregulator complex composition
but potentially in the patterns of posttranslational modi- blad et al., 1995; Ait-Si-Ali et al., 1998), thereby giving
them control of important components of the cellularfication of these complexes in response to endocrine sig-
nals (Figure 3) are awaited with anticipation. At any rate, transcriptional machinery. Moreover, genetic diseases
attributable to coregulators have been reported (Petrijcoregulator posttranslational modification is emerging as
an elegant mechanism whereby a relatively small num- et al., 1995), which often give rise to skeletal and CNS
abnormalities and altered hormonal response.ber of factors can govern a broad array of transcriptional
responses. Finally, we speculate that the coactivator/corepressor
levels in different individuals may explain in part the
remarkable differences in individual phenotypes ob-Physiology of Coregulators
The list of physiological implications of coregulators is served throughout the human population. Although
structural gene allelism is an important factor, the differ-expanding rapidly, and it is likely not an overstatement
to suggest that these molecules seem to be the missing ences are of such magnitude, and the genes of individu-
als so similar, that other factors must come into play.links to explanations for many cellular phenomena. For
example, the cellular balance of coactivators and core- Given that coactivators act at the amplification step in
gene expression, a few percent difference in the inher-pressors affords a smooth and tightly controlled induc-
tion curve for NR-mediated gene expression. Increased ited coactivator levels (or allelism of coactivators) in the
population could underlie major alterations in hormone-coactivator would likely provide a more rapid transcrip-
tional response and has been shown to shift the hor- mediated development of, for example, the musculo-
skeletal and organ systems.monal induction curve to the left (Chen et al., 2000). This
might explain, at least in part, some of the well-known
variability in the degree of individual human responses Looking to the Future
In contrast to the strides taken toward clarifying coacti-to steroid hormones. Since some of the same coactiva-
tors are used in interphase gene regulation and in regula- vator mechanism at the promoter, issues concerning
the physiological and metabolic roles of coactivatorstion of cell cycle control factors, there exists a link for
communication between those two processes. Viruses and their tissue-specific functionality are only beginning
Review
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to be elucidated. The problem has been compounded out in isolation but are coordinately regulated, such that
by the nature of assays routinely employed in the field, initiation and reinitiation of transcription are coupled to
such as cell transfection and in vitro protein-protein 5-capping, polyadenylation, and RNA splicing (Lewis
interaction assays, which do not readily lend themselves and Tollervey, 2000, and references therein). In addition
to meaningful comparison. While these approaches to the C-terminal domain of RNA polymerase II, NRs
have made tangible progress in the mechanistic charac- may serve as additional platforms to target the myriad
terization of coactivator function, they permit only tenta- factors required for optimum gene expression, thereby
tive extrapolation when the biological functions of intact justifying the need for a large and diverse cohort of
coregulators, and coregulator complexes, are consid- coactivators.
ered. Assays employed to considerable effect more re- It is widely anticipated that medical therapy and phar-
cently have been those that interrogate the patterns of maceutical development will benefit significantly from
recruitment of receptors and coregulators to DNA in the plethora of recent molecular data. Future clinical
living cells, such as chromatin immunoprecipitation strategies should clarify the extent to which the reported
(ChIP; Shang et al., 2000), and the real-time imaging relationships between altered coactivator (or corepres-
techniques that afford an insight into the cellular dynam- sor) levels and tumor progression and treatment influ-
ics of these factors (McNally et al., 2000; Stenoien et ence the course of these diseases (Anzick et al., 1997;
al., 2001). A caveat in attempting to reconcile data gener- Lavinsky et al., 1998; Graham et al., 2000). It is logical
ated by these techniques, however, is that while ChIP that high coactivator levels could afford tumors a selec-
is a composite freeze-frame of promoter occupancy in tive gene expression advantage for proliferation, but
millions of cells, real-time imaging focuses on a chronol- definitions both of the signaling pathways that interact
ogy of events in a single cell. with and modulate coactivator function (Figure 3) and
Much remains to be explored in coregulator biology the biological consequences of this modification are of
over the next decade, and the field is aptly poised to major current importance. The concept of membrane
build upon the current store of knowledge of their mech- receptor pathway and nuclear pathway collaboration in
anistic properties. A primary objective is the definition the cell is accepted, but the mechanisms by which MAP
of a reasonably complete list of coregulators and their kinases, protein kinase A, IK, and stress-activated
enzymatic functions, with a subsequent goal of under- pathways specifically influence coactivator function is
standing and cataloging the target genes responsive to insufficiently defined at present. It can be reasonably
combinations of individual coactivators and corepres- speculated, however, that overexpression of a coactiva-
sors. At that point, we can then assign regulated gene tor (e.g., p/CIP/AIB1/SRC-3) in the presence of high lev-
sets to coregulators and begin to elucidate the presump- els of growth factors, growth factor receptors, or MAP
tive metabolic (Herzig et al., 2001; Yoon et al., 2001) and kinase activity, could likely result in the development of
developmental (Ito et al., 2000) roles of coregulators and a very aggressive cancer.
their coordinate activation of target gene sets that have Finally, it is likely that the recent coregulator discover-
evolved to perform specific functions. Such information ies and the information on their mechanisms of action
would go a long way to substantiate a role for coactiva- will expedite the development of new pharmaceutical
tors as overall coordinators for the efficient expression leads. It is already clear that the existence of coregula-
of gene sets controlling metabolic functions. tors greatly impacts the tissue-specific pharmacology
We have suggested that the heterogeneity of coacti- of mixed antagonist/agonist drugs such as the SRMs.
vators can be explained in part by their organization into Evidence exists that the specific coregulator levels in
multifunctional complexes. But is their function simply cellular or cell-free systems contribute to the relative
to enhance the transcriptional potency of NRs—or is a antagonist versus agonist activity of a ligand on NR
complex array of other functions yet to be uncovered? activation (Smith et al., 1997). Although X-ray structures
Putting aside the likely consideration that coregulator of the LBD and coactivator interaction surfaces have
functions outside the nuclear compartment will be dis- been solved (Nolte et al., 1998; Shiau et al., 1998), it may
covered, it is almost certain that the heterogeneity is be that the full impact of these structural studies on new
dedicated in part to subsequent downstream transcrip- drug development will not be realized until the full-length
tion-coupled reactions required to effect gene expres-
NRs are crystallized and complexes of N-terminal-inter-
sion. A great deal of the current experimental work in
acting and C-terminal-interacting coregulators are de-
our field has been devoted to elucidating the mechanisms
termined.by which NRs and coactivators initiate and reinitiate tran-
scription. This is undoubtedly of great importance, but if
Conclusiona gene is activated maximally for transcription, it will be
Combinatorial control of gene expression by NRs re-of little import to expression of the function of that gene
quires their recruitment of functionally distinct coregula-if elongation, RNA splicing, 5- and 3-RNA processing,
tor complexes (Figure 2), which appear to communicatemRNA packaging and transport, and translation, be-
with each other through intricate sequences of post-come rate limiting. The fact that NRs might act as tem-
translational modifications. It has become clear that aplates for assembly of factors that enhance these subse-
definition of coregulators that restricts their roles to am-quent reactions should not be surprising, and evidence
plifying or silencing the transcriptional output of NR-suggests that coactivators are likely to be the factors
regulated promoters is insufficient to account for theirthat mediate many of these downstream NR-related
elaborate functionality. The collective efforts of labora-events (Monsalve et al., 2000). This concept is reason-
tories in this field have identified more highly complexably consistent with current thinking within the tran-
and intricate subplots in this narrative than was initiallyscription field, which purports that the major steps lead-
ing to the formation of mature mRNAs are not carried anticipated, and it is increasingly appreciated that li-
Cell
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